Financial Performance - Total revenue reached $319 million, a 10% year-over-year decrease[2] - Adjusted EBITDA hit a record $41.4 million, up 12% year-over-year[2, 3] - Avocado volume sold increased by 13% year-over-year, reaching 181.5 million pounds[2, 3] - Average selling price decreased by 27% year-over-year to $1.39 per pound[2] Segment Performance - Marketing & Distribution segment adjusted EBITDA increased by 11% due to higher volume[4] - International Farming adjusted EBITDA increased significantly by 211%[4] - Peruvian orchards produced approximately 105 million pounds of exportable avocados, more than double the prior year's production[4] Cash Flow and Capital Expenditure - The company generated $89 million in operating cash flow for the full year[5] - The company generated more than $180 million of operating cash flow over a two-year period[5] - Fiscal year 2026 capital expenditure is expected to decrease to approximately $40 million[5]

Financial Performance - Scholastic achieved a 13% growth in adjusted EBITDA during the second quarter of fiscal year 2026[5] - Revenue increased by 1% to $551.1 million in Fiscal 2026 Q2, compared to $544.6 million in Fiscal 2025 Q2[9] - Operating income increased by 11% to $82.9 million in Fiscal 2026 Q2, compared to $74.7 million in Fiscal 2025 Q2[9] - Diluted earnings per share increased by 27% to $2.17 in Fiscal 2026 Q2, compared to $1.71 in Fiscal 2025 Q2[9] - Adjusted EBITDA reached $122.5 million in Fiscal 2026 Q2, compared to $108.7 million in Fiscal 2025 Q2[9] Segment Performance - Children's Book Publishing and Distribution revenue increased by 4% to $380.9 million, with operating income up 7% to $108.8 million[10] - Education Solutions revenue decreased by 13% to $62.2 million[10] - International revenue increased by 3% to $89.5 million, with operating income up 80% to $12.8 million[10] Strategic Initiatives and Capital Allocation - The company unlocked over $400 million through sale-leaseback transactions to advance capital allocation priorities[5, 6] - Nearly $500 million was returned to shareholders, reducing share count by approximately 25%[6] Fiscal Year 2026 Outlook - The company affirmed its adjusted EBITDA outlook of $146 to $156 million, including a $14 million partial-year impact from sale-leasebacks[12] - Free cash flow is expected to exceed $430 million, reflecting sale-leaseback net proceeds[12]

Project Highlights - The DeLamar Heap Leach Project demonstrates robust economics with an after-tax NPV5% of $774 million (base case) and $1.7 billion (spot)[16] - The project boasts a competitive after-tax IRR of 46% (base case) and 89% (spot)[16] - The initial capital expenditure is estimated at $389 million[16] - The project anticipates an average gold equivalent (AuEq) production of 106,000 ounces over the life-of-mine (LOM) and 119,000 ounces annually for the first 5 years[16] - The mine life is projected to be 10 years, with a total payable AuEq of 1.1 million ounces[16] Cost and Economics - LOM cash costs are estimated at $1,179 per AuEq ounce, while all-in sustaining costs (AISC) are projected at $1,480 per AuEq ounce[16] - The project has a payback period of 1.8 years (base case) and 1.0 years (spot)[16] - The NPV-to-capex ratio is 2.0 (base case) and 4.4 (spot)[16] Mineral Reserves - The DeLamar Project has proven and probable oxide mineral reserves of 119,972 kilotonnes with an average gold grade of 0.33 g/t, containing 1,259 koz of gold[27] - The project also holds proven and probable oxide mineral reserves of 119,972 kilotonnes with an average silver grade of 13.56 g/t, containing 52,305 koz of silver[27]

2026 Budget & Guidance - Development capital expenditures are budgeted between $180 million and $190 million[10] - The company forecasts average production between 39,000 and 41,000 barrels of oil equivalent per day (boe/d)[10] - Oil and liquids are expected to comprise approximately 81% of the production mix[10] - Adjusted Funds Flow (AFF) is projected to be between $325 million and $375 million, or $1.75 to $2.00 per share[10] - Free Funds Flow (FFF) is forecasted between $120 million and $170 million, or $0.65 to $0.95 per share, resulting in a free funds flow yield of 25% to 35%[10] - Net debt at the end of 2026 is estimated to be between $645 million and $695 million, with a net debt to adjusted EBITDA ratio of 1.4x to 1.7x[10] Sensitivity Analysis - A $5.00 change in WTI oil price is expected to impact AFF by approximately $50 million[13] - A 1,000 barrel per day change in oil production is projected to impact AFF by approximately $25 million[13] - A $0.01 change in the CAD/USD exchange rate is expected to impact AFF by approximately $8 million[13] - A $0.50 change in AECO gas price is projected to impact AFF by approximately $3 million[13] Development Program Highlights - Approximately 33% of the 2026 development capital is allocated to Open Hole Multi-Lateral (OHML) locations in Southeast Saskatchewan (SE SK)[9, 15] - The company plans for 32 OHML locations in 2026 and has identified over 300 OHML locations in SE SK[15] - The company plans for 23 conventional wells[19]

Financial Performance - Total revenue for fiscal year 2025 was $158.2 million, compared to $112.1 million in fiscal year 2024[31] - The net loss for fiscal year 2025 was $(191.4) million, compared to $(156.8) million in fiscal year 2024[31] - Adjusted EBITDA for fiscal year 2025 was $(74.4) million, compared to $(101.1) million in fiscal year 2024[31] - The company ended fiscal year 2025 with $341.8 million in total cash, restricted cash, and cash equivalents[10] - Backlog as of October 31, 2025, was $1.16 billion, compared to $1.19 billion as of October 31, 2024[34] Operational Highlights - The company is operating at a 41 MW per year annualized production rate as of October 31, 2025[10, 28] - The Torrington, CT factory has the potential to accommodate an estimated annualized production capacity of up to 350 MW per year with additional capital investments[10, 26] - The company commissioned 22 1.4-MW replacement fuel cell modules in fiscal year 2025 and expects to commission 14 more in fiscal year 2026 for Gyeonggi Green Energy (GGE)[39] Strategic Focus - The company is focusing on a data center strategy, leveraging AI-driven demand for new opportunities[9] - The company's systems do not require utility interconnection when operating in off-grid mode and are a durable baseload alternative[12] - The company emphasizes potential margin expansion through higher production utilization and sustained cost discipline in fiscal year 2026[10]

Financial Performance - Q1 Fiscal Year 2026 - Organic ASV (Annual Subscription Value)增长5.9%[7]，达到23.9亿美元[19] - 调整后的营业利润率为36.2%[7] - 调整后的摊薄每股收益为4.51美元[7] - 营收为6.08亿美元，同比增长6.9%[26]；有机营收为6.00亿美元，同比增长6.0%[26, 38] - 调整后的营业收入为2.20亿美元，同比增长3.0%[26] - 调整后的净利润为1.70亿美元，同比增长0.9%[26] Key Operational Metrics - 客户ASV保留率超过95%[24] - 用户数量达到239,863，同比增长10%[24] - 客户保留率为91%，比2025年第一季度上升约30个基点[24] - ASV大于1万美元的客户数量为9,003，同比增长9%[24] Growth by Global Segments and Firm Type - 美洲地区的ASV为15.57亿美元，增长6%[20] - 欧洲、中东和非洲地区（EMEA）的ASV为5.88亿美元，增长4%[20] - 亚太地区的ASV为2.45亿美元，增长8%[20] - 机构买方的ASV为11.57亿美元，增长4%[20] - Dealmakers的ASV为4.56亿美元，增长6%[20] - 财富管理的ASV为3.74亿美元，增长10%[20] - 市场基础设施的ASV为4.03亿美元，增长7%[20] Fiscal Year 2026 Guidance - 有机ASV增长预计为1亿至1.5亿美元，约占4.2%至6.2%[32] - 营收预计为24.23亿至24.48亿美元[32] - GAAP营业利润率预计为29.5%至31.0%[32] - 调整后的营业利润率预计为34.0%至35.5%[32] - GAAP摊薄每股收益预计为14.55美元至15.25美元[32] - 调整后的摊薄每股收益预计为16.90美元至17.60美元[32]

Leadership Transition - David McCreight was announced as Interim President & CEO, and Thomas Folliard as Interim Executive Chair, effective December 1, 2025[6] - Former Chief Executive Officer, Bill Nash, stepped down from his position and as a member of the Board effective December 1, 2025[9] Q3 2026 Financial Performance - Net earnings per share decreased by 24.7% year-over-year to $0.64[24, 27] - Total gross profit decreased by 12.9% year-over-year to $590.0 million[24] - SG&A expense increased by 1.0% year-over-year to $581.4 million[24] - CarMax Auto Finance (CAF) income increased by 9.3% year-over-year to $174.7 million[27] Sales Performance - Total vehicles bought decreased by 11.7% year-over-year to 238,000 units[24] - Retail used unit sales decreased by 6.2% year-over-year[24] - Wholesale unit sales decreased by 9.0% year-over-year[24] Capital Allocation - The company repurchased $201.6 million in shares of common stock[17]

Transaction Overview - TMTG will merge with TAE in an all-stock transaction, aiming to create a pro forma company capitalized to fund a utility-scale fusion plant and grow media and technology franchises[5] - The transaction is expected to close in mid-2026, pending customary closing conditions and shareholder approval[5] - Post-merger, TMTG/TAE are expected to own approximately 50% each on a fully diluted basis[6] - TMTG has agreed to provide up to $200 million in cash to TAE, with an additional $100 million available upon initial filing of the Form S-4[6] Pro Forma Company Strategy - The pro forma company aims to deliver clean, affordable, and reliable fusion energy, targeting utility-scale power generation with plants scaled to 350-500 MWe[8, 9] - The company plans to advance TAE's proprietary technology, which is considered safe, deployable, and reliable for baseload power to meet AI-driven demand[7, 9] - The company intends to construct its first utility-scale 50 MWe fusion power plant, with site location and construction commencing in 2026, targeting initial power operations in 2031[21] Financials and Leadership - The pro forma company will have $3.1 billion of financial assets on its balance sheet as of Q3 2025[28] - TAE has raised $1.3 billion in private capital to date[7, 25] - The pro forma company will be governed by a nine-member board, with a majority being independent, including Devin Nunes, Michl Binderbauer, Donald J Trump Jr, and Michael B Schwab (Chairman)[6, 7] TAE Technology and Innovation - TAE has a 27-year history of fusion research, having built five fusion reactors to date[6, 7, 19] - TAE has over 400 employees, including 62 Ph Ds, and has been granted over 1,600 patents[7] - TAE is targeting fusion-generated electricity by 2031, with future commercial power plants expected to be sized at 350-500 MWe[11, 20]

MICVO Monotherapy Efficacy - MICVO monotherapy demonstrated a validated efficacy signal in 2L+ R/M HNSCC, with a 46% confirmed ORR and a 92% DCR (n=13, 5.4 mg/kg)[4] - In the Phase 1 monotherapy dose expansion study at 5.4 mg/kg, Arm 1 (post-PD1/post-Platinum) showed a 60% confirmed ORR (N=5)[32] - Arm 2 (post-PD1/post-EGFRi) in the monotherapy study showed a 25% confirmed ORR (N=4), exceeding the PI benchmark of 20%+[32] - MICVO monotherapy at 5.4 mg/kg demonstrated clear activity with deep responses and exceptional disease control[35] MICVO + KEYTRUDA® Combination Efficacy - MICVO combined with KEYTRUDA® showed a promising emerging efficacy profile in 1L/2L+ R/M HNSCC, with a 71% confirmed ORR and 100% DCR (n=7, 3.6 mg/kg & 4.4 mg/kg)[4] MICVO Safety and Tolerability - MICVO at 5.4 mg/kg in R/M HNSCC showed no Grade 4 or Grade 5 ADC payload TRAEs of interest[40] - Initial data supports a lack of overlapping toxicities observed between MICVO and KEYTRUDA®[52] Market and Clinical Development - FDA aligned on a 2L+ monotherapy pivotal trial design for MICVO[4] - The US R/M HNSCC market is large, growing, and relatively uncrowded, making it ripe for innovation[17] - Projected 2029 US market data shows a significant number of drug-treatable patients, with ~31K in 1L, ~21K in 2L, and ~8K in 3L[18]

Lasofoxifene (Metastatic Breast Cancer) - The global metastatic ER+/HER2- breast cancer market is expected to grow from approximately $10.9 billion in 2025 to roughly $15.9 billion by 2029[23] - Lasofoxifene, combined with abemaciclib, demonstrated a potential best-in-class median Progression-Free Survival (PFS) of 13 months in a heavily pre-treated mESR1 population in the Phase 2 ELAINE-2 trial[26, 27, 50] - In the ELAINE-1 Phase 2 study, lasofoxifene delivered a median PFS of 24.2 weeks compared to 16.2 weeks with fulvestrant in ESR1-mutant breast cancer[48] - Approximately 70% of all breast cancers are ER+/HER2- subtype[23, 32] - Lasofoxifene reduced new onset breast cancer by 83% in a large prevention trial[30] - The ELAINE-3 registrational Phase 3 trial is ongoing, with topline results expected in mid-2027 and over 50% enrollment[16, 17, 57, 138, 139] - Assuming approximately 10% market penetration, lasofoxifene has a peak market sale potential of over $1 billion in the US market[81] ATH-1105 (ALS) - Approximately 225,000 people globally are affected by ALS, with roughly 33,000 cases in the US[98] - ATH-1105 is a CNS-penetrant positive modulator of HGF as a potential treatment for ALS[103] - A Phase 2 POC study in ALS is planned to start in the first half of 2026, with topline results expected in 2027[18, 19, 140, 141] Financial - A PIPE financing of up to $236 million, including $90 million upfront, provides cash runway through data readout and into 2028[137]